Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis

Completed

Conditions: Multiple Myeloma

Interventions: Other: No Intervention

First Posted Date: 2018-04-24

Last Posted Date: 2021-02-08

Lead Sponsor: Takeda

Target Recruit Count: 943

Registration Number: NCT03506386

Locations: 🇧🇷
Centro de Hematologia e Oncologia (CEHON), Salvador, BA, Brazil
🇧🇷
Hospital Sao Rafael, Salvador, BA, Brazil
🇧🇷
Hospital das Clinicas da UFG, Goiania, GO, Brazil

and more 14 locations

A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Alogliptin
Drug: Pioglitazone
Drug: SYR-322-4833 BL

First Posted Date: 2018-04-18

Last Posted Date: 2019-08-08

Lead Sponsor: Takeda

Target Recruit Count: 72

Registration Number: NCT03501277

Locations: 🇷🇺
Non-governmental healthcare Institution Road Clinical Hospital at the station Yaroslavl JSC Russian Railways, Yaroslavl, Russian Federation

A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Niraparib

First Posted Date: 2018-04-13

Last Posted Date: 2021-11-09

Lead Sponsor: Takeda

Target Recruit Count: 9

Registration Number: NCT03497429

Locations: 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)

Completed

Conditions: Crohn Disease
Colitis, Ulcerative
Inflammatory Bowel Disease

First Posted Date: 2018-04-04

Last Posted Date: 2022-02-08

Lead Sponsor: Takeda

Target Recruit Count: 246

Registration Number: NCT03488030

Locations: 🇦🇷
Hospital Privado de Cordoba, Cordoba, Argentina
🇦🇷
Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo, Caba, Buenos Aires, Argentina
🇦🇷
Sanatorio Mater Dei, Caba, Buenos Aires, Argentina

and more 4 locations

Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

Phase 1

Completed

Conditions: Celiac Disease

Interventions: Drug: TIMP-GLIA

First Posted Date: 2018-04-03

Last Posted Date: 2020-06-05

Lead Sponsor: Takeda

Target Recruit Count: 23

Registration Number: NCT03486990

Locations: 🇺🇸
Mayo Gastroenterology Research Unit, Rochester, Minnesota, United States
🇺🇸
Jacksonville Center For Clinical Research, Jacksonville, Florida, United States
🇺🇸
Mass General Hospital Translational and Clinical Research Centers, Boston, Massachusetts, United States

and more 1 locations

Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

Phase 3

Completed

Conditions: Peripheral Arterial Diseases

Interventions: Drug: Placebo
Drug: Actovegin

First Posted Date: 2018-03-19

Last Posted Date: 2020-10-28

Lead Sponsor: Takeda

Target Recruit Count: 366

Registration Number: NCT03469349

Locations: 🇰🇿
"National scientific centre of oncology and transplantology", Astana, Kazakhstan
🇷🇺
SBHI of Ryazan region Regional clinical cardiological dispensary, vessel surgery department/ FSBI of Ryazan Region "Ryazan State Medical Univesity n.a. I.P. Pavlov" of MoH of Russia, Ryazan, Russian Federation
🇬🇪
Center of Vascular and Heart Disease, Tbilisi, Georgia

and more 17 locations

A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-438ASA
Drug: TAK-438
Drug: Aspirin

First Posted Date: 2018-03-07

Last Posted Date: 2019-11-19

Lead Sponsor: Takeda

Target Recruit Count: 276

Registration Number: NCT03456960

Locations: 🇯🇵
Fukuoka Mirai Hospital, Fukuoka, Japan

A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Daratumumab
Drug: Dexamethasone

First Posted Date: 2018-02-20

Last Posted Date: 2024-07-03

Lead Sponsor: Takeda

Target Recruit Count: 61

Registration Number: NCT03439293

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Pacific Cancer Medical Center, Anaheim, California, United States
🇺🇸
Research Medical Center - Kansas City, Kansas City, Missouri, United States

and more 25 locations

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

Phase 1

Completed

Conditions: Healthy Adult Participants

Interventions: Drug: Vortioxetine

First Posted Date: 2018-02-19

Last Posted Date: 2019-06-27

Lead Sponsor: Takeda

Target Recruit Count: 28

Registration Number: NCT03437564

Locations: 🇯🇵
Nishi Kumamoto Hospital, Kumamoto, Japan

A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-536

First Posted Date: 2018-02-15

Last Posted Date: 2019-06-10

Lead Sponsor: Takeda

Target Recruit Count: 12

Registration Number: NCT03434977

Locations: 🇯🇵
Fukuoka Mirai Hospital, Fukuoka, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy